Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

NCT07636785 is registered in ClinicalTrials.gov with VM Discovery, Inc. as lead sponsor.

NCT NCT07636785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07636785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors
Lead sponsor
VM Discovery, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 16, 2026
Completion date
December 31, 2031
Enrollment
111 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), hepatocellular carcinoma (hcc), metastatic uveal melanoma, nonsmall cell lung cancer, renal cell carcinoma (rcc)